neurobion advance 100 mg + 50 mg + 1 mg tabletki powlekane
p&g health germany gmbh - thiamini nitras + pyridoxini hydrochloridum + cyanocobalaminum - tabletki powlekane - 100 mg + 50 mg + 1 mg
clindamycin hameln 150 mg/ml roztwór do wstrzykiwań lub infuzji
hameln pharma gmbh - clindamycini phosphas - roztwór do wstrzykiwań lub infuzji - 150 mg/ml
help4skin septi-spray 1 mg/g + 20 mg/g aerozol na skórę
zakłady farmaceutyczne polpharma s.a. - octenidini dihydrochloridum + phenoxyethanolum - aerozol na skórę - 1 mg/g + 20 mg/g
zypsila 20 mg kapsułki twarde
krka, d.d., novo mesto - ziprasidonum - kapsułki twarde - 20 mg
zypsila 80 mg kapsułki twarde
krka, d.d., novo mesto - ziprasidonum - kapsułki twarde - 80 mg
zypsila 40 mg kapsułki twarde
krka, d.d., novo mesto - ziprasidonum - kapsułki twarde - 40 mg
zypsila 60 mg kapsułki twarde
krka, d.d., novo mesto - ziprasidonum - kapsułki twarde - 60 mg
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroksysmal - selektywne leki immunosupresyjne - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
ampicilin+sulbactam aptapharma 2 g + 1 g proszek do sporządzania roztworu do wstrzykiwań / do infuzji
apta medica internacional d.o.o. - ampicilinum + sulbactamum - proszek do sporządzania roztworu do wstrzykiwań / do infuzji - 2 g + 1 g
ampicilin+sulbactam aptapharma 1 g + 0,5 g proszek do sporządzania roztworu do wstrzykiwań / do infuzji
apta medica internacional d.o.o. - ampicilinum + sulbactamum - proszek do sporządzania roztworu do wstrzykiwań / do infuzji - 1 g + 0,5 g